BioSpace News Archive

Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), announced today that the Independent Data Monitoring Committee (IDMC) recommended the continuation of the REVEAL Phase 1/2 trial and that dosing of the second patient in the first cohort can proceed.

SEKISUI Diagnostics announces the launch of the OSOM COVID-19 Antigen Home Test to diagnose COVID-19 at home.

Corbus Pharmaceuticals Holdings, Inc. today announced that Yuval Cohen , Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the BTIG Virtual Biotechnology Conference, to be held August 7-8, 2023.

Axial3D today announced that it is the first to receive FDA clearance for an automated, AI-driven, cloud-based segmentation platform for orthopedic trauma, orthopedic, maxillofacial, and cardiovascular applications.

UroGen Pharma Ltd. today announced the grants of inducement restricted stock units (“RSUs”) and options (“Options”) to a new employee, Michael Louie, SVP Medical Affairs & Clinical Development, in connection with his commencing employment with UroGen.

Chronic back pain is a significant issue in the United States, affecting millions of individuals annually. According to the National Institute of Neurological Disorders and Stroke, approximately 80% of adults will experience back pain at some point.

NeuroTrauma Sciences, LLC today announced the appointment of Kevin Pong, PhD, MBA as Chief Business Officer.

Applying AI to a single apical four chamber (A4C) view echocardiogram provides accurate information to detect heart failure with preserved ejection fraction (HFpEF), according to research published today in JACC Advances.

MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or the “Company”) today announced statistically significant positive topline results from its randomized Phase 2 study of oral TNF-α inhibitor, MYMD-1® in patients with chronic inflammation associated with sarcopenia, or age-related frailty.

Qylur today announced that it has been awarded a phase I Small Business Innovation Research (SBIR) contract from the Department of Defense Air Force AFWERX SBIR program, for its SNIM® AI platform.